Company Overview
Cencora (COR) is a leading pharmaceutical wholesaler and services provider, operating globally to distribute drugs and healthcare products. The company (based near Philadelphia) was previously AmerisourceBergen Corporation, trading under ticker “ABC” until a name and ticker change to Cencora (COR) in August 2023 to reflect its unified global presence ([2]). Cencora’s business generates massive revenue but at razor-thin margins typical of drug distributors. In FY2023, for example, the company’s revenue was $262.2 billion (up ~9.9% year-on-year) while operating income was about $2.34 billion – an operating margin under 1% ([4]) ([4]). Net income attributable to Cencora was roughly $1.73 billion in FY2023, yielding a net profit margin well below 1% ([4]) ([4]). This underscores that distribution is a high-volume, low-margin business.
Despite those thin margins, Cencora has delivered steady growth. Its U.S. Healthcare Solutions segment (the largest division) saw revenue rise about 10.7% in FY2023, reflecting strong demand for specialty pharmaceuticals ([4]). Notably, specialty drugs – complex therapies for conditions like cancers and, recently, popular weight-loss injections – have been a key growth driver. In the latest quarter of FY2024, U.S. segment revenue jumped nearly 12% to $67.2 billion, boosted by surging sales of high-cost GLP-1 agonist weight-loss medicines (such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound) ([5]). These specialty products carry higher dollar revenues and have contributed to Cencora beating profit and revenue estimates and raising its earnings forecasts in 2024 ([5]). The company’s international segment (expanded by the 2021 acquisition of Alliance Healthcare in Europe) provides additional growth, though currency effects (e.g. inflationary pressures in Turkey) have sometimes crimped profit margins ([4]). Overall, Cencora’s core business appears fundamentally strong, with secular tailwinds from an aging population and new therapies. This strength makes the recent stake reduction by Silver Oak curious, suggesting there may be other factors at play like valuation, capital allocation, or emerging risks.
Dividend Policy and Cash Flow Coverage
Cencora has a long track record of paying and steadily raising dividends. The company currently pays a quarterly dividend of $0.55 per share, which was increased by 8% from $0.51 in late 2024 ([6]). This brings the annualized payout to $2.20 per share, representing a dividend yield of roughly 0.75% at recent share prices ([3]). While that yield is modest (below 1%), it reflects the stock’s strong price performance and Cencora’s emphasis on growth and share buybacks over a high payout. In fact, Cencora’s dividend growth streak stands at 15 consecutive years of increases, though typically in the mid-single-digit percentage range annually ([7]). The company’s payout ratio is quite conservative – on the order of 20–25% of earnings ([7]) – which means the dividend is very well-covered by profits. This low payout leaves ample retained cash flow for other uses like reinvestment and share repurchases.
(function(){var btn=document.getElementById(‘ahg-close-4');if(!btn)return;btn.addEventListener(‘click',function(){var p=document.getElementById(‘ahg-sticky-4′);if(!p)return;p.style.display='none';});})();
Importantly, Cencora generates robust cash flows relative to its dividend obligations. In FY2023, net cash from operating activities was about $3.91 billion, and even after capital expenditures, adjusted free cash flow was $3.13 billion for the year ([4]). This comfortably covered the roughly $430 million paid in dividends (further highlighting a payout ratio under one-quarter of free cash flow). In effect, the dividend could be raised significantly and still remain sustainable if management chose – but instead Cencora has allocated much of its excess cash to buy back shares and fund acquisitions. For example, the company has been repurchasing stock, including opportunistic buybacks of shares from Walgreens Boots Alliance as that major shareholder sold down its position ([8]). (Walgreens, once a ~13% owner, has steadily reduced its stake – from 13% to 12% in mid-2024 via a $400 million Cencora share repurchase ([8]), and further down to ~6% by early 2025 through additional sales and buybacks.) This strategy of buybacks, along with earnings growth, has driven Cencora’s adjusted EPS upward at a double-digit clip while keeping the dividend growing at a measured pace. From an income-investor perspective, the key point is that Cencora’s current yield is quite low, but the dividend is extremely well-covered – leaving room for continued growth or the flexibility to redirect cash toward share retirement and strategic investments. Given the modest income payout, investors like Silver Oak may view the stock more as a growth play than a dividend play, which can influence their allocation decisions.
One note of caution is that Cencora’s cash flow generation can be uneven quarter-to-quarter due to working capital swings. The business must continuously buy inventory and extend credit to pharmacies, so timing differences can impact reported operating cash in the short term. For instance, in the first nine months of FY2025, the company’s operating cash flow was temporarily constrained by large working capital outflows – resulting in only ~$92 million of adjusted free cash flow over that period (after backing out one-time settlement gains) ([9]). Such volatility means that while Cencora’s annual cash flows are strong, interim periods can show dips (e.g. from a bulge in receivables or an upfront legal payout). Nonetheless, over a full year the company consistently produces billions in excess cash, far above what’s needed to cover interest and dividends. The solid cash coverage underlines that Cencora’s dividend is not at risk; if anything, it could be ramped up more aggressively, but management has chosen a balanced capital allocation (small dividend increases alongside heavier buybacks and debt management). This conservative dividend policy might be a slight drawback for yield-focused investors, but it provides Cencora flexibility and resilience.
Leverage and Debt Profile
Cencora’s balance sheet is reasonably strong, with moderate debt and manageable leverage. As of the end of FY2023, the company carried about $4.15 billion of long-term debt ([4]). Cencora also held a substantial cash reserve of approximately $2.59 billion ([4]), so net debt (debt minus cash) stood near $1.6 billion – a very low figure relative to the company’s EBITDA and equity market value. By comparison, FY2023 EBITDA (earnings before interest, taxes, depreciation, and amortization) was on the order of $3.3 billion (roughly $2.34 billion operating profit plus $0.96 billion depreciation/amortization) ([4]) ([4]), which means net leverage was well under 0.5× EBITDA. Even on a gross basis, debt/EBITDA was roughly 1.2× – indicating a light debt load for a company of Cencora’s size and stability.
URGENT: Get “Trump\'s Secret Fund” — Learn How to Collect Royalty Checks
Limited report reveals the #1 American oil & gas royalty play that can start paying monthly — with just $50.
Start w/ $50
Yes — Send My Report
Fast download • Instant access • Seats limited
Interest expense is also very well covered by earnings. In FY2023, Cencora’s net interest expense was about $229 million ([4]), while income before taxes was $2.16 billion ([4]). This implies an EBIT/interest coverage ratio of roughly 9–10×, a comfortable cushion. Put another way, interest consumed only ~0.08% of revenue ([4]), reflecting the low cost of debt and the fact that Cencora doesn’t heavily rely on leverage to finance its operations. The company’s investment-grade credit ratings affirm this solidity – Cencora’s senior unsecured debt is rated BBB+ by S&P and Baa2 by Moody’s (mid-to-high tier investment grade) ([10]) ([11]). Those ratings have allowed Cencora to issue new debt at reasonable rates even amid rising interest yields. For example, in late 2024 Cencora raised $1.8 billion in fresh bonds (split across maturities in 2027, 2029, and 2035) with coupons in the 4.6%–5.15% range ([12]). In early 2024 it also issued $500 million of 2034 notes at ~5.125% ([13]). These transactions refinanced some nearer-term borrowings and funded corporate needs (like shareholder returns), while pushing out major debt maturities well into the future. The company’s nearest significant bond maturities now appear to be in 2027, giving ample breathing room.
It’s worth noting that Cencora does have a large long-term liability related to opioid litigation settlements, which is carried on the balance sheet separate from the debt. As one of the three largest U.S. drug distributors, the company was part of a nationwide opioid settlement finalized in 2021. Cencora’s accrued litigation liability stood at $5.06 billion as of Sept 30, 2023, down slightly from $5.46 billion a year prior ([4]). This decrease indicates that Cencora has begun making the scheduled settlement payments. The opioid settlement payments are to be paid out over many years (stretching roughly into the mid-2030s), rather than a lump sum, which helps mitigate the cash strain. In FY2023 the company actually recorded a small net credit for opioid-related expenses (approximately $25 million credit) because its prior accruals exceeded the final payments or adjustments that year ([4]) ([4]). Essentially, while the remaining $5+ billion obligation is substantial, it is a known liability being whittled down steadily. Cencora’s strong operating cash flows (typically $3–4 billion annually) make the yearly settlement installments (on the order of a few hundred million dollars) manageable, though they do act as an added claim on cash that might otherwise go to faster dividend hikes or more aggressive expansion. Investors should keep an eye on this liability’s trajectory. But overall, Cencora’s leverage is low and financial headroom is high – a positive sign that debt is unlikely to stress the company. In fact, conservative balance sheet management is likely one reason the stock commands a relatively high valuation multiple (investors see it as a stable, low-risk earnings generator). Silver Oak’s partial exit likely isn’t driven by any credit concerns, because the company’s debt profile is quite healthy.
Valuation and Performance
Cencora’s share price has performed strongly over the past two years, reflecting robust earnings growth and reduced uncertainty (post-opioid settlement). The stock currently trades around $290–$300 per share, which gives a market capitalization near $57 billion ([3]). In valuation terms, Cencora is not a cheap stock – but it’s roughly in line with its industry peers after the recent run-up. Based on consensus earnings forecasts, Cencora’s shares trade at about 17× forward earnings ([14]). Using the company’s own guidance, adjusted earnings per share (EPS) for fiscal 2024 came in around $13.76 (non-GAAP) ([15]), and for fiscal 2025 management is now projecting $15.85–$16.00 in adjusted EPS ([9]). At the current price, that puts the forward price-to-earnings (P/E) ratio in the high teens – in the same ballpark as rivals McKesson and Cardinal Health, which also trade in the mid-teens P/E range. It’s worth noting Cencora’s valuation multiple has expanded in recent years. Historically, drug distributors often traded at low double-digit P/Es due to razor-thin margins and past legal overhangs. But with the opioid cloud largely lifted and the company delivering consistent growth, the market is affording Cencora a higher multiple. For instance, the stock’s trailing P/E (based on GAAP FY2023 EPS of $8.53) is over 30×, though on an adjusted basis (excluding one-time charges) the trailing P/E is closer to ~21×. In short, investors are paying a premium for Cencora’s stability and growth prospects, and the stock appears fully valued relative to its recent history. This might be one factor behind Silver Oak’s trimming – locking in gains after a significant rally, at a price that bakes in a lot of good news.
In terms of performance, the company’s financial momentum has been strong, which justifies much of the optimism. Cencora has exceeded earnings expectations for several quarters, propelled by the growth in specialty pharmaceuticals. As noted, third-quarter FY2024 results saw revenue and profit beat forecasts and led management to raise the annual profit outlook ([5]). Adjusted EPS grew about 15% in fiscal 2024 (to $13.76 from $11.99 the prior year) ([15]), and the outlook for FY2025 implies another ~15% jump at the midpoint of guidance. Such growth is impressive for a mature distributor and is partly due to operational execution and share buybacks, but also the high demand for new high-value therapies. For example, sales of complex drugs for diabetes/obesity, oncology, and other specialty areas are boosting revenue at double-digit rates ([5]), and Cencora, with its expansive distribution network, captures a small margin of a very large dollar volume. The result is modest margin expansion in absolute terms: gross profit was up 8% in FY2023 ([4]) and adjusted gross profit up 8.1% in FY2024 ([15]), even as gross margin percentage stayed around ~3.3–3.5%. Cencora’s adjusted operating income and EPS are growing faster than revenue, indicating operating leverage and effective cost control. The company has also been active in strategic acquisitions to expand its service offerings – for instance, in late 2024 it agreed to acquire Retina Consultants of America (a network of specialty eye-care clinics) to bolster its specialty physician services ([16]). Moves like these diversify revenue and could provide higher-margin streams over time, though they also introduce integration tasks.
Despite these positives, prospective investors have to weigh how much of this growth is already reflected in the stock price. At ~17× forward earnings and an EV/sales ratio under 0.3× (common for distributors given the huge revenues), Cencora’s valuation assumes it can continue to churn out high-single-digit to low-double-digit EPS growth in coming years. Any slowdown in specialty drug tailwinds or an unexpected hit to margins could temper that growth and thus pressure the share price. Additionally, the stock’s dividend yield of ~0.7% ([3]) is quite low, meaning the bulk of investor return must come from price appreciation. If the market starts to see Cencora as “priced for perfection,” even a solid company can experience a stock pullback. It’s possible that Silver Oak’s partial exit simply reflects a prudent rebalancing after a big price run – essentially, taking some profit off the table because Cencora’s valuation is no longer a bargain and the yield doesn’t provide much cushion. In summary, Cencora’s current valuation is fair to slightly rich, supported by strong performance but leaving less margin for error.
Risks and Red Flags
While Cencora’s business is fundamentally robust, there are a number of risk factors and potential red flags that investors (including Silver Oak) may be monitoring:
– Opioid Litigation Liabilities: The multibillion-dollar opioid settlement remains a significant overhang. Cencora is obligated to pay over $5 billion (cumulatively) in settlement funds over about 15+ years ([4]). These payments will continue to siphon hundreds of millions in cash annually. Although the worst uncertainties are behind (settlement amount fixed and reserves taken), any misstep – such as additional claims or slower earnings growth – could make the payouts more burdensome. It’s essentially a debt-like obligation that drags on free cash flow. On a related note, reputational and regulatory scrutiny of distributors in the opioid aftermath will persist, which could mean tighter compliance costs or constraints on certain high-risk product sales.
– Thin Margins & Pricing Pressure: Cencora operates on razor-thin margins (gross margin ~3.4%, operating margin <1% ([4]) ([4])). This leaves little room for error. Any price or cost shock can quickly erode profitability. For instance, if drug manufacturers reduce distributor compensation, or if payers squeeze fees, Cencora can’t easily offset that given the slim margin structure. Similarly, inflation in operating costs (labor, fuel for logistics, etc.) must be passed through or absorbed efficiently. The company’s recent results have benefited from deflationary LIFO inventory accounting (a credit when prices fall) ([4]) – but if drug price inflation resumes, Cencora could see accounting charges that hurt reported earnings. Managing costs ultra-tightly is imperative, and any operational hiccup (like a warehouse issue, IT system failure, or unforeseen expense) could have an outsize percentage impact on earnings.
– Customer Concentration & Contract Risks: The pharmaceutical distribution industry is dominated by a few large customers and contracts. Cencora’s fortunes are tied to retaining major clients like retail pharmacy chains, health systems, and insurers/PBMs. Notably, Walgreens Boots Alliance (which was a large shareholder) is also a major customer through a long-term distribution agreement. If Walgreens (now reducing its equity stake) or any other big client were to shift volume to another distributor or vertically integrate, Cencora could lose a chunk of business. The top few customers likely account for a significant portion of revenue – a common situation in this sector – which means relationship stability is critical. Contracts are typically multi-year, but on renewal, pricing terms could be pressured. The ongoing relationship with Walgreens, in particular, bears watching now that Walgreens has cut its ownership interest (it went from ~13% to ~6%) – there’s no immediate sign of change in their supply agreement, but the strategic partnership aspect is diminished ([8]). Any signal that a big client might diversify suppliers or exert pricing pressure is a risk to Cencora’s forecasted growth.
– Regulatory and Political Risks: As a key player in drug distribution, Cencora is exposed to the regulatory environment for healthcare and pharmaceuticals. Potential drug pricing reforms in the U.S. (such as Medicare negotiating prices or importation of cheaper drugs) could indirectly affect distributors. For example, if drug prices drop significantly due to regulation, Cencora’s revenue (which is largely pass-through cost) would drop accordingly; profit impact is less direct, but could still be felt if fees are percentage-based. Additionally, any regulation that deters use of certain drugs (opioids, controlled substances) or adds compliance burdens (track-and-trace requirements, tighter licensing) can increase operating costs. Internationally, Cencora faces currency and economic risks – e.g., emerging markets with volatile currencies (like Turkey, where hyperinflation has required special accounting treatment ([4])) or geopolitical issues that might disrupt global supply chains. Also, antitrust scrutiny is always possible given only three companies dominate U.S. drug distribution – while there’s no indication of action, regulators keep an eye on oligopolies in healthcare.
– Competition and Disintermediation: Cencora competes primarily with two other giants (McKesson and Cardinal Health) in the traditional distribution channel. The competitive dynamics have been generally rational, but pricing battles for contracts can squeeze margins periodically. Moreover, new distribution models or entrants could pose a long-term threat. Tech-driven disruptors like Amazon have made forays into pharmacy (though not full-scale wholesale distribution yet), and large retailers or payers have shown interest in more control over their supply chain. If major pharmacy chains, insurers, or hospital groups attempt to bypass wholesalers or form joint procurement alliances, distributors like Cencora might see volume or margin pressure. So far, the value proposition of big distributors (efficient logistics, financing inventory, regulatory compliance) has kept the model intact. But the healthcare landscape evolves – e.g., biosimilars and specialty drugs might be distributed via alternate channels, or manufacturers might grow direct-to-provider deliveries in some cases. This isn’t an immediate threat but is an open question for the long run.
– Cash Flow Volatility & Working Capital Needs: As noted earlier, Cencora’s cash flow can be volatile due to working capital swings. In FY2025 to date, free cash flow was negligible through Q3 because the company had significant cash tied up in inventory and receivables ([9]). Some of this was likely temporary (e.g., building inventory for new product launches or timing of payments). Nonetheless, poor cash conversion in a given period can be a red flag – it might signal inventory management issues or slower collections. If such trends persisted, it could indicate that growth is requiring more cash (perhaps as Cencora expands into services or international markets) or that suppliers/customers are getting more favorable terms at Cencora’s expense. So far, management has expressed confidence that cash generation will normalize (and indeed historically it has), but it’s a point to watch. Any deterioration in cash conversion cycle efficiency would be a concern, as it might force the company to rely more on debt for liquidity needs.
– Leadership Transition: Cencora has undergone a leadership change with the completion of a succession plan in 2024 – longtime CEO Steven Collis transitioned out, and the company’s new CEO (likely Robert Mauch, previously an executive vice president) took the helm ([9]). While this was a planned and orderly transition, any change at the top introduces some uncertainty. The new leadership may set different strategic priorities or have a different risk appetite (for M&A, leverage, etc.). Thus far there’s no indication of a strategic shift – the messaging has been continuity and focus on “strategic drivers” like digital transformation and productivity ([9]). However, investors will be attentive to execution under the new CEO. If performance slips or strategy shifts unexpectedly, it could be viewed as a red flag attributable to the management change.
Overall, none of these risks appear to undermine the core viability of Cencora’s business model in the near term – but they do provide reasons for investors to be vigilant. In particular, valuation-related risk (that the stock price may not have much margin for error) combined with any of the above factors could lead an investor to trim their holdings. Silver Oak’s stake reduction could simply reflect a prudent response to the balance of reward vs. risk at current levels: the company is executing well, but it faces ongoing obligations and operates in a dynamic healthcare market with thin margins.
Open Questions and Conclusion
Cencora’s situation brings up several open questions for investors moving forward:
– Is the Stock Overvalued or Fairly Valued? With Cencora trading around 17× forward earnings – a higher multiple than its historical norm – one key question is whether future growth will fully justify this valuation. The company has benefited from exceptional tailwinds (like the boom in specialty drugs and weight-loss medications driving volumes ([5])). If these tailwinds persist, Cencora could continue its earnings climb and perhaps even merit the premium. However, if growth moderates to more typical mid-single-digit levels, the current stock price might be on the rich side. Silver Oak’s partial exit suggests some investors see limited upside in the near term. New investors must decide if Cencora still offers an attractive risk-adjusted return at this price, or if much of the good news is already baked in.
– How Will Capital Allocation Evolve? Cencora has been balancing dividend growth, share buybacks, and M&A. With the dividend payout ratio so low (~20% ([7])), one open question is whether the company might start returning more cash to shareholders via a higher dividend or accelerated buybacks, especially after the opioid payments taper off in later years. Alternatively, will management prefer to reinvest in growth opportunities (e.g., more acquisitions like the Retina Consultants deal) to expand the business portfolio? The company’s strategy here will influence the kind of investors it attracts – income-focused vs. growth-focused. A more aggressive dividend could draw income investors but would mark a shift from the current approach. Thus far, management seems content with modest dividend hikes and heavier buybacks (which were used opportunistically to absorb Walgreens’ share sales ([8])). It remains to be seen if that mix changes once the Walgreens stake is fully unwound and the company has even more free cash at its disposal.
– What Happens as Walgreens Exits? Walgreens Boots Alliance’s sell-down of Cencora shares is nearly complete, and this raises a couple of questions. First, will Walgreens maintain its long-term distribution contract with Cencora at the same terms once it’s no longer an equity holder? Walgreens has been under its own financial pressures and might seek cost savings – though switching distributors or renegotiating could be disruptive, it’s not impossible in the future. So far, there’s no sign of a change, but investors will watch any commentary on that key relationship. Second, once Walgreens is fully out, the technical overhang on Cencora’s stock should lift (fewer large secondary sales to worry about). Will the absence of that seller provide support to the share price, or has it already been absorbed by the market? In early 2025, Cencora did repurchase some shares alongside Walgreens’ sales ([17]), indicating an effort to minimize market impact. The resolution of this process could remove a mild cloud over the stock.
– Can Recent Growth Drivers Sustain? Cencora’s recent growth has leaned heavily on volume expansion in specialty drugs, including high-priced new therapies. An open question is whether these trends are sustainable. For instance, the GLP-1 agonist drugs for weight loss are a major boon now ([5]), but competition and eventual price moderation could reduce their outsized impact. Similarly, the oncology and specialty pipeline is strong at the moment – but if drug innovation slows or if more biosimilars (cheaper alternatives) enter the market, the revenue growth rate might slow for distributors. Cencora’s ability to keep growing profit at ~10%+ annually could be tested in a more normalized environment. The company is trying to augment growth by expanding services (through its consulting, logistics, and physician services arms), which could help diversify income. How well these adjacencies perform is another question. Investors will be gauging if Cencora can maintain say high-single-digit EPS growth organically or if it needs continual acquisitions and share buybacks to hit targets. The answer will determine if the current valuation multiple is warranted or not.
– Are There Unseen Risks? Finally, any investor must ask if there are any “unknown unknowns” lurking. In the past, AmerisourceBergen was blindsided by the magnitude of opioid liability. Today, one might wonder about other potential liabilities or disruptions – for example, product liability in specialty distribution (handling of hazardous drugs), cybersecurity risks (given large IT systems managing the drug supply chain), or macroeconomic shocks (like a severe recession reducing healthcare utilization). None of these are evident problems now, but the low-margin nature of the business means unforeseen hits can quickly affect profitability. Cencora’s rebranding itself is an open question: it signals a new era, but it’s mostly cosmetic – will it have any impact on business perception or is it merely a footnote? Likely the latter, but only time will tell if “Cencora” builds the same reputation that “AmerisourceBergen” had in the industry.
In conclusion, Cencora (COR) is a financially solid company executing well in a vital industry. It boasts steady growth drivers, a prudent dividend policy, strong creditworthiness, and diminishing legacy liabilities. These strengths have driven the stock to all-time highs and a richer valuation, which in turn may be prompting some investors to rebalance – as we saw with Silver Oak’s stake reduction ([1]). Their selling doesn’t appear to reflect any immediate crisis at the company, but rather the calculus of capturing gains and managing exposure. For investors evaluating Cencora now, it boils down to confidence in the company’s continued growth versus the lofty expectations already embedded in the share price. Cencora’s fundamentals remain healthy, but the stock is no longer an under-the-radar bargain. Going forward, keeping an eye on how the company navigates its slim margins, deploys its ample cash flows, and adapts to the evolving pharma landscape will be key. These factors will ultimately determine if Cencora can deliver enough upside to satisfy shareholders – or if more stakeholders follow Silver Oak in trimming their stakes at these elevated levels. Each of the topics discussed – dividend trajectory, leverage use, valuation metrics, and risk management – feeds into that broader judgment. As of now, Cencora stands as a high-quality business with a balanced risk/reward profile, and thoughtful investors will weigh those attributes when deciding whether to buy, hold, or trim exposure in line with their own objectives and risk appetite. The question “Why did Silver Oak cut their stake?” can likely be answered by a mix of profit-taking and prudent risk management, given where the company and stock sit today – not due to a loss of faith in Cencora’s operations, but recognition that even great companies have their price. ([1]) ([3])
Sources
- https://etfdailynews.com/2025/09/24/silver-oak-securities-incorporated-lowers-stock-holdings-in-cencora-inc-cor/
- https://businesswire.com/news/home/20230830469400/en/AmerisourceBergen-becomes-Cencora-in-alignment-with-the-company%E2%80%99s-growing-global-footprint-and-central-role-in-pharmaceutical-access-and-care
- https://macrotrends.net/stocks/charts/COR/cencora/dividend-yield-history
- https://edgar.secdatabase.com/1587/114085923000147/filing-main.htm
- https://reuters.com/business/healthcare-pharmaceuticals/cencora-raises-annual-profit-forecast-strong-demand-specialty-medicines-2024-07-31/
- https://businesswire.com/news/home/20241106645310/en/Cencora-Reports-Fiscal-2024-Fourth-Quarter-and-Year-End-Results
- https://dividendpedia.com/cencora/
- https://investor.walgreensbootsalliance.com/news-releases/news-release-details/walgreens-boots-alliance-sells-shares-cencora-400-million/
- https://investor.cencora.com/news/news-details/2025/Cencora-Reports-Fiscal-2025-Third-Quarter-Results/default.aspx
- https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3369953
- https://app.researchpool.com/index.php/provider/moodys-investors-service/cencora-inc-cor-moodys-ratings-assigns-baa2-rating-to-cencoras-new-senior-notes-J5jVcEnbfP
- https://investor.cencora.com/news/news-details/2024/Cencora-Prices-500-Million-4.625-Senior-Notes-Due-2027-600-Million-4.850-Senior-Notes-Due-2029-and-700-Million-5.150-Senior-Notes-Due-2035/default.aspx
- https://investor.cencora.com/news/news-details/2024/Cencora-Prices-500-Million-5.125-Senior-Notes-Due-2034/default.aspx
- https://ca.finance.yahoo.com/quote/COR/key-statistics/
- https://marketscreener.com/quote/stock/CENCORA-INC-9428091/news/Cencora-Reports-Fiscal-2024-Fourth-Quarter-and-Year-End-Results-48272919/
- https://stocktitan.net/news/COR/cencora-reports-fiscal-2024-fourth-quarter-and-year-end-ty60d7wsztxe.html
- https://investor.walgreensbootsalliance.com/news-releases/news-release-details/walgreens-boots-alliance-sells-shares-cencora-approximately-11
For informational purposes only; not investment advice.